key: cord-1002822-xdh4w9fg
authors: Willis, Van C.; Arriaga, Yull; Weeraratne, Dilhan; Reyes, Fredy; Jackson, Gretchen P.
title: A narrative review of emerging therapeutics for COVID-19
date: 2020-07-20
journal: Mayo Clin Proc Innov Qual Outcomes
DOI: 10.1016/j.mayocpiqo.2020.07.004
sha: f9c32e8afdaad367ef4c5950e652e31494f5925a
doc_id: 1002822
cord_uid: xdh4w9fg

Abstract The novel coronavirus SARS-CoV-2, causal agent of COVID-19, quickly spread around the world resulting in the most aggressive pandemic experienced in over 100 years. Research into targeted therapies and vaccines has been initiated on an unprecedented scale and speed but will take months and even years to come to fruition. Meanwhile, the efficacy of emerging therapeutics for use in treating COVID-19 is feverishly being investigated to identify the best available treatment options for dealing with the current wave of disease. This review provides frontline clinicians with a pragmatic summary of the current state of the rapidly evolving evidence supporting emerging candidate therapeutics for COVID-19. Two main categories of pharmaceutical therapeutics are showing promise—those with antiviral activity directly addressing infection and those that counteract the inflammatory cytokine storm induced by severe disease. Preliminary results suggest that other approaches such as convalescent plasma therapy and lung radiation therapy may have some efficacy. The current clinical evidence for potential treatments is preliminary – often small retrospective series or early results from randomized trials – and the science is evolving rapidly. Long-term results from large, well-designed randomized trials will provide definitive evidence of therapeutic effectiveness and are likely months away. The trial landscape for promising therapies is described.

The novel coronavirus SARS-CoV-2, causal agent of COVID-19, quickly spread around the world resulting in the most aggressive pandemic experienced in over 100 years. Research into targeted therapies and vaccines has been initiated on an unprecedented scale and speed but will take months and even years to come to fruition. Meanwhile, the efficacy of emerging therapeutics for use in treating COVID-19 is feverishly being investigated to identify the best available treatment options for dealing with the current wave of disease. This review provides frontline clinicians with a pragmatic summary of the current state of the rapidly evolving evidence supporting emerging candidate therapeutics for COVID-19. Two main categories of pharmaceutical therapeutics are showing promise-those with antiviral activity directly addressing infection and those that counteract the inflammatory cytokine storm induced by severe disease. Preliminary results suggest that other approaches such as convalescent plasma therapy and lung radiation therapy may have some efficacy. The current clinical evidence for potential treatments is preliminary -often small retrospective series or early results from randomized trials -and the science is evolving rapidly. Long-term results from large, welldesigned randomized trials will provide definitive evidence of therapeutic effectiveness and are likely months away. The trial landscape for promising therapies is described.

The novel systemic acute respiratory syndrome (SARS) coronavirus-2 (SARS-CoV-2), the causal agent of COVID-19, appeared in December 2019 in Wuhan, China, and its subsequent worldwide spread prompted the World Health Organization (WHO) to declare a global pandemic and international public health emergency. 1 As of June 29, 2020, over 10 million cases have been reported in 188 countries/regions across the world resulting in over 500,000 deaths. 2 High mortality and hospitalization rates of COVID-19, especially in older patients with comorbidities, 3 have stressed global health systems. Historically, the clinical approach to newly emergent pandemic threats has been largely reactive due to the absence of established therapeutic interventions. 4 In a pandemic, there are inherent challenges to conducting randomized clinical trials with the urgent need to decrease mortality. Treatment based on preliminary science has ethical implications and, in many cases, the opportunity to rigorously study treatments before the pandemic subsides is lost. The rigor of scientific evidence for clinical benefit must be balanced with the expediency of treatment need.

Numerous therapies with a wide variety of mechanisms have been proposed for treating COVID-19. The aim of this narrative review is to provide frontline clinicians with a pragmatic summary of the current state of the rapidly evolving evidence supporting emerging therapeutics for COVID-19. We describe the mechanism of action and provide a succinct summary of the science supporting each treatment strategy and the pipeline of clinical trials.

To capture rapidly emerging COVID-19 science, all publication types (e.g., peer-reviewed research, editorials, preprints) were included in this review. Evidence was identified primarily through a search for publications with a 'treatment' tag in the National Library of Medicine's LitCovid literature hub 5, 6 through June 29, 2020. Review of citations within these articles identified additional relevant articles. Studies were selected if they contained clinical data on COVID-19 therapeutics with near-term availability. Clinical trial landscape assessment for emerging therapies was performed by searching ClinicalTrials.gov 7 for recruiting/open interventional trials on June 29, 2020, using a condition/disease query of COVID-19, SARS-CoV-2, and 2019-nCoV.

Treatment development for COVID-19 has focused on repurposing existing drugs targeting the virus directly or mitigating the excessive inflammatory response it triggers. Convalescent plasma therapy (CPT) and drugs that were used for similar diseases including SARS, Middle East respiratory syndrome (MERS), and Ebola have emerged as treatment options due to their known safety profiles and availability. The current evidence for the most promising COVID-19 emerging therapies identified in a LitCovid literature hub search of 5,788 total publications is reviewed below and summarized in Table 1 .

Remdesivir is an adenosine analogue developed to treat Ebola. Its effects derive from inhibition of viral replication and RNA synthesis. 8, 9 Data supporting treatment of SARS-CoV-2 infection with remdesivir include established potency against coronaviruses in vitro 8 and in mouse 10 and primate 11 models. In-vitro studies with SARS-CoV-2 measured a half maximal effective concentration (EC 50 ) of 0.77μM and inhibition of infection in Huh-7 cells. 12 Combination with emetine may enhance viral inhibition. 13 Clinically, multiple case reports and series from Canada, Europe, Japan, and the United States have provided early promising results of treatment with remdesivir, usually in combination with other agents. [14] [15] [16] [17] [18] [19] In the first reported double-blind, randomized, placebo-controlled trial (RCT) of remdesivir, the time to clinical improvement was similar to the control group but numerically shorter for patients treated within 10 days of symptom onset. This trial unfortunately did not attain the predetermined sample size due to containment of the outbreak in China. 20 reported in a non-peer-reviewed forum and showed little benefit in clinical outcomes 39 as did a randomized trial of 22 patients comparing LPV/RTV to chloroquine (CQ). 40 A study of LPV/RTV pharmacokinetics in 8 COVID-19 patients suggested that current doses are likely 60-120 fold too low at trough to achieve EC50 concentrations, 41 perhaps explaining the overall lack of effect seen in studies to date.

Induction of an inflammatory cytokine storm is a well-described phenomenon in patients with SARS, 42 and it has been observed in early investigations of SARS-CoV-2 infection. 43, 44 Consequently, the effects of immunomodulators on COVID-19 are being evaluated. Since interleukin 6 (IL6) levels have been observed to be consistently elevated in patients with severe COVID-19, [45] [46] [47] [48] inhibition of the IL6-receptor with monoclonal antibodies such as tocilizumab and sarilumab are of great interest for the treatment of COVID-19. Janus kinase (JAK) inhibitors such as baracitinib and ruxolitinib are also being considered for treating COVID-19-associated cytokine storm. Baracitinib was identified as a candidate COVID-19 therapeutic agent through search of a knowledge graph generated in part by machine learning. 49, 50 However, there are concerns about drug-induced lymphocytopenia that may limit the utility of this small molecule targeted agent in the management of COVID-19. 51 Based on previous reports of possible benefits, including decreased mortality and shorter hospital stay, from properly prescribed systemic glucocorticoid therapy for critically ill patients with SARS, 52, 53 glucocorticoid management of COVID-19 is also being explored.

A study of 21 patients in China receiving tocilizumab in addition to standard of care showed clinical improvements including fever resolution and improved oxygen saturation within 24 hours following treatment. 54 One retrospective evaluation of 15 patients receiving tocilizumab showed reductions in C-reactive protein and IL6 levels in all patients except those who were critically ill and received only one dose. 55 Retrospective analyses of 100 56 and 85 57 patients receiving tocilizumab plus lopinavir/ritonavir or hydroxychloroquine (HCQ) compared with lopinavir/ritonavir or HCQ alone found, respectively, that 25% of patients receiving tocilizumab experienced death/and or ICU admission and a hazard ratio (HR) for death of 0.035. In a retrospective study of 100 consecutive patients receiving tocilizumab in Italy, 77% of patients' conditions stabilized or improved while in 23% their condition worsened. 58 A prospective open, single-arm multicenter study of 63 patients receiving tocilizumab demonstrated improvement in respiratory and laboratory parameters. In this same study, administration of tocilizumab within 6 days of admission was associated with increased likelihood of survival (HR 2.2). 59 Conversely, a 21-patient retrospective analysis of tocilizumab treatment in Italy did not find reductions in ICU admission or 7-day mortality rates. 60 Interestingly, a retrospective analysis of 78 patients receiving tocilizumab suggested that IL6 levels in hyperglycemic patients persisted at levels 5-fold higher than normoglycemic patients and that treatment failed to attenuate risk of severe outcomes in these patients. 61 Publication of in vitro experiments showing the JAK inhibitor baricitinib's ability to reduce viral load in human primary liver spheroids and a 4-patient case series demonstrating improvement in signs and symptoms including cough, fever, IL6 levels, and viral load seem to validate its identification as a potential therapeutic for COVID-19. 62 Addition of baricitinib to LPV/RTV therapy in 12 Italian patients resulted in improvements to clinical and respiratory parameters in the following 2 weeks. 63 A retrospective multicenter study in 191 patients showed 6% and 17% reductions in 2-week fatality rate and ICU admission in the baricitinib arm (baricitinib plus LPV/RTV) compared with controls (HCQ plus LPV/RTV). 64 In a 41-patient, multicenter, singleblind, randomized trial of a different JAK inhibitor, ruxolitinib, patients receiving ruxolitinib had numerically faster, but not statistically significant, clinical improvements over patients receiving placebo plus standard of care. 65 However, a retrospective study of 14 patients in Germany with progressive hyperinflammation resulting from COVID-19 showed a 58% decline in inflammation scores 7 days after treatment with ruxolitinib, and 76% of patients had clinical improvement on the WHO ordinal scale. 66 Preliminary studies of glucocorticoid therapy in COVID-19 to date present mixed results regarding their effects on mortality, clinical parameters, and length of stay. 67 difference in viral clearance through 28 days between patients treated with HCQ or standard of care. However, post-hoc analyses suggest that symptom alleviation was faster in patients receiving HCQ when accounting for confounding from other antiviral therapies. 80 No difference in mortality, ICU admission, or ventilation rates was observed with HCQ treatment in retrospective analyses of 368 US patients 81 and 191 French patients 82 who received HCQ, HCQ added to azithromycin, or who were unexposed to HCQ. Likewise, in a 1,376-patient observational study at a single hospital and a 1,438-patient multicenter retrospective analysis in New York, there was no significant association between HCQ use and intubation or death (hazard ratio 1.04) 83 or HCQ and azithoromycin use and mortality. 84 The first randomized, double-blind, placebo-controlled study of postexposure prophylactic HCQ treatment showed no apparent decrease in incidence between treatment and placebo groups (11.8% vs 14.3%) in the 821 participants at moderate or high risk of exposure to COVID-19. 85 In one open-label nonrandomized trial in 36 French patients, HCQ treatment virologically cured 57% of patients (100% of patients when used in conjunction with azithromycin) within 6 days of treatment compared to 12.5% of control patients. 86 Although a follow-up study of azithromycin combined with HCQ in 80 additional French COVID-19 patients confirmed significant reductions in viral load and improved clinical outcomes 87 , the first study has been criticized for a lack of randomization, patients dropped from analysis, and the chosen thresholds for determining viral presence. 88, 89 A statement from the International Society of Antimicrobial Chemotherapy indicated that the article didn't meet their expected standards. 90 Interestingly, a separate team's efforts to replicate viral clearance in a 12-patient case series using HCQ azithromycin combination therapy found that only 20% of patients using this treatment tested negative for SARS-CoV-2 at days 5 to 6 after treatment. 91 However, a retrospective analysis of 1,061 patients (95% with mild disease) by the same group whose studies have been questioned, showed a good clinical outcome (no death, hospitalization for 10 days or more, viral shedding, or transfer to ICU) in 91.7% of patients and mortality in 0.9%. 92 A randomized trial of 22 patients comparing CQ to LPV/RTV, 40 a retrospective analysis of 48 patients receiving HCQ compared with 502 patients receiving standard therapy, 93 and a non-peer-reviewed pre-print describing a double-blinded RCT of HCQ therapy in 62 patients with mild disease also seem to indicate some benefit in time to clinical recovery or mortality from CQ or HCQ treatment. 94 As a result of their potentially severe toxicities, the safety of CQ and HCQ in COVID-19 is in question. In a retrospective analysis of 95 patients receiving CQ for COVID-19 in the Netherlands, 23% of patients had a QTc interval exceeding 500ms during treatment, 95 but in France, less than 6% of 73 patients had prolongated QTc measurements greater than 500ms after HCQ + azithromycin treatment. 96 One arm of a double-blind randomized trial of CQ in Brazil with dosing of 600mg twice daily was halted by the data safety monitoring board after 6 days as a result of QT prolongation. Fatality rates for the duration of the trial showed no difference to historical data from similar patients, and only 7% of patients tested negative for virus during that time. 97 Pharmacokinetic simulations have highlighted potential safety concerns with current CQ and HCQ dosing and questioned their ability to achieve concentrations required for antiviral activity. 98, 99 

Virus-specific antibodies present in CPT have been used as late-line treatments in recent epidemics including SARS, Ebola, H1N1 influenza, MERS, and throughout the history of medicine. 100 A retrospective study of therapeutic plasma exchange in patients with sepsis and multi-organ failure that is currently under peer-review suggests that for patients with pneumonia as the primary source of sepsis, this approach may improve mortality rates. 101 On 112 In all of these studies, patients treated with CPT also received other treatments, including antiviral therapies, so the contribution of CPT to patient recovery is currently unclear. However, a non-peer reviewed study of 5,000 patients receiving CPT as part of the US FDA Expanded Access Program resulted in a serious adverse event rate <1%, suggesting that CPT in COVID-19 appears to be safe. 113

The development of novel drugs and vaccines targeting SARS-CoV-2 is a fundamental step in the control of the COVID-19 pandemic. A detailed review of these efforts is beyond the scope of this work but it is important to highlight that dozens of small molecule, biologic, and RNA-based therapies are being actively developed for the treatment of COVID-19 (reviewed in 114 ) and will be essential for containing future waves of disease. On June 1, 2020, a first of its class targeted COVID-19 therapy, LY-CoV555, a monoclonal antibody targeting SARS-CoV-2, began clinical evaluation in a randomized, double-blind, placebo controlled phase I clinical trial assessing its safety and tolerability in hospitalized patients with COVID-19. 115 Likewise, COVID-19 vaccine development has unfolded at unprecedented scale and speed-as of June 24, 2020, over 150 active COVID-19 vaccine projects are underway, 16 of which have begun human testing. 116 Development of effective COVID-19 vaccines is crucial for enabling long-term management of the pandemic.

As of June 29, 2020, an assessment of clinical trials for COVID-19 emerging therapies on ClinicalTrials.gov produced 1,154 search results. The number and type of trials for the therapies included in this review are summarized in Table 2 . Emerging trials of note include the use of low-dose radiation therapy to suppress the cytokine storm and resultant pulmonary inflammation and edema 117 as well as evaluation of ivermectin based on its in vitro anti-SARS-CoV-2 effects. 118 The scientific community has responded to the COVID-19 pandemic with rapid implementation and execution of well-designed and accessible RCTs (examples shown in Table 3 ). An illustrative example is the SOLIDARITY trial, a WHO-sponsored, adaptive RCT open to any patient with confirmed SARS-CoV-2 infection worldwide. 119 Based on institutional drug availability, patients were initially randomized to standard of care or to any of 4 arms: remdesivir, CQ/HCQ, LPV/RTV, or LPV/RTV plus interferon beta-1a. Strengths of SOLIDARITY are the simplicity of eligibility criteria that enable enrollment of a large volume of patients along with a robust scientific methodology, electronic endpoint data capture, and an adaptive design to allow modification of treatment arms based on evolving evidence. An example of adaptation is the halting of the HCQ arm of SOLIDARITY on June 17, 2020 based on initial results not showing reduction in mortality compared with standard of care. 119 Similarly, the NIH's ORCHID trial of HCQ was halted after the data safety and monitoring board determined that HCQ was unlikely to be beneficial to hospitalized patients with COVID-19. 120

This review of available data about the efficacy and safety of emerging therapies for COVID-19 provides a few promising results, but the evidence base is growing and evolving rapidly. Clinicians, scientists, patients, and their families must be cautious about interpretation and application of early results. The rapid evolution of COVID-19 knowledge combined with amplification by the lay press has resulted in several misinterpretations and high-profile study retractions. 121, 122 Clinical trials of therapeutic, prophylactic, and preventive interventions are underway, and therapeutic development is being expedited by unprecedented collaboration and removal of unnecessary barriers in the scientific process. The actions of the scientific community in combating the COVID-19 pandemic provide hope that after the current global health crisis, the acceleration of preventive, diagnostic, and therapeutic discoveries will become the "new normal" for science. This approach might be replicated for a wide variety of complex diseases in need of effective treatments and cures such as cancer, obesity, Alzheimer's disease, diabetes, or opioid and alcohol addiction. The COVID-19 pandemic is a formidable healthcare challenge but also an opportunity to foster the collaboration of multiple stakeholders; utilization of technologies for big data management, storage, and sharing; and the rapid and continuous knowledge integration necessary to accelerate the bench to bedside process. In the long run, as a public health emergency of international concern, COVID-19 provides the necessary lessons for developing rapid learning health care systems that can help expedite the discovery of novel therapeutics and their efficient introduction into practice. 

Director-General's opening remarks at the media briefing on COVID-19 -11

Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 (COVID-19) in Wuhan, China: a retrospective study

Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic

Keep up with the latest coronavirus research

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio

Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir

Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro

First Case of 2019 Novel Coronavirus in the United States

Delayed Initiation of Remdesivir in a COVID-19 Positive Patient

Early experience with remdesivir in SARS-CoV-2 pneumonia

Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States

Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post_treatment hospitalisation status

Compassionate Use of Remdesivir for Patients with Severe Covid-19

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI)

Treating COVID-19 with

Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19)

Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). medRxiv

Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients

Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. medRxiv

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

COVID-19: combining antiviral and antiinflammatory treatments. The Lancet Infectious Diseases

BARICITINIB -A JANUASE KINASE INHIBITOR -NOT AN IDEAL OPTION FOR MANAGEMENT OF COVID 19

Treatment of severe acute respiratory syndrome with glucosteroids: the Guangzhou experience

Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak

Effective treatment of severe COVID-19 patients with tocilizumab

Tocilizumab treatment in COVID-19: a single center experience

Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients

Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia

Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in

Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19

Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE). Microorganisms

Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients

Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients

Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact

Retrospective, multicenter study on the impact of baricitinib in COVID-19 moderate pneumonia

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation

Effectiveness and safety of glucocorticoids to treat COVID-19: a rapid review and meta-analysis

Effect of Dexamethasone in Hospitalized Patients with COVID-19: Preliminary Report. medRxiv

Comparison of the Antiviral Activity in vitro of some Non-steroidal Antiinflammatory Drugs

Antihistaminics, local anesthetics, and other amines as antiviral agents

Effect of chloroquine on the growth of animal viruses

In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine

Of chloroquine and COVID-19

Chloroquine for influenza prevention: a randomised, doubleblind, placebo controlled trial

A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults

On Chikungunya Acute Infection and Chloroquine Treatment. Vector-Borne and Zoonotic Diseases

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)

Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial

Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19

Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data

Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19

Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study Mediterranee Infection

Statistical review of Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

Comments on the Hydroxychloroquine/Azithromycin Study and Lessons for Future Clinical Trials of COVID-19 Treatments. Researchgate. 2020. 90. Statement on IJAA paper Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection

Full-length title: Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France

Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19

QT interval prolongation under hydroxychloroquine/ azithromycin association for inpatients with SARS-CoV-2 lower respiratory tract infection

Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial

Chloroquine dosage regimens in patients with COVID-19: Safety risks and optimization using simulations

Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease

Convalescent plasma as a potential therapy for COVID-19. The Lancet Infectious Diseases

A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19

Investigational COVID-19 Convalescent Plasma -Emergency INDs

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection

Treatment with convalescent plasma for COVID-19 patients in Wuhan

Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea

Effectiveness of convalescent plasma therapy in severe COVID-19 patients

Treatment of COVID-19 Patients with Convalescent Plasma

Use of Convalescent Plasma in Hospitalized Patients with Covid-19 -Case Series

INFUSION OF CONVALESCENT PLASMA IS ASSOCIATED WITH CLINICAL IMPROVEMENT IN CRITICALLY ILL PATIENTS WITH COVID-19: A PILOT STUDY

Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients. The Journal of Infectious Diseases

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial

Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients. medRxiv

Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases

Lilly Begins World's First Study of a Potential COVID-19 Antibody Treatment in Humans

WHO. DRAFT landscape of COVID-19 candidate vaccines -24

Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia: Planned Day-7 Interim Analysis of a Registered Clinical Trial. medRxiv

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

Solidarity" clinical trial for COVID-19 treatments

NIH halts clinical trial of hydroxychloroquine

Retraction: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19

RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. The Lancet

Total recruiting/open interventional trials (1,154) listed from a search of ClinicalTrials.gov on June 29, 2020, using a condition/disease query of COVID-19, SARS-CoV-2, and 2019-nCoV.